New Beijing News (Reporter Zhang Zhaohui) On July 18th, BeiGene Bureau announced the appointment of Aaron Rosenberg as the company's Chief Financial Officer and appointed Rosenberg as a senior management personnel. The appointment will take effect from July 22, 2024.
Wang Aijun will officially resign as the Chief Financial Officer of the company on July 19, 2024. After resigning as Chief Financial Officer, Wang Aijun will continue to provide services to the company as a senior advisor to assist in the transition of the Chief Financial Officer, with a service period until August 31, 2024.
The announcement shows that Rosenberg has served Merck&Co. for over 20 years and is a senior global financial executive. He has been serving as Senior Vice President and Corporate Treasurer of Merck&Co. since 2021. Before serving as the Corporate Treasurer of Merck&Co., he joined the company in 2003 and held various leadership positions in the global finance department with expanding responsibilities. Rosenberg served as Vice President and Financial Head of Merck Animal Health from 2015 to 2018, leading a global team of 120 people; From 2018 to 2021, served as the Senior Vice President of Corporate Strategy and Planning at the company, responsible for leading the company's business transformation team and serving as the Head of Financial Planning and Analysis. Rosenberg holds a Bachelor's degree in Finance from the University of Florida Warrington School of Business and a Master's degree in Business Administration from the Stern School of Business at New York University.